Neuphoria Therapeutics Inc. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Neuphoria Therapeutics Inc. (NEUP) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of $183.08 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-09-18
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was $183.08K.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was -$460.30K, a 376.59% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $166.42K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-06-30 | $183.08K 10-K · filed 2026-09-18 |
| 2024-06-30 | -$460.30K 10-K · filed 2025-09-29 |
| 2023-06-30 | $166.42K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |